Preventive Vaccines Market - Growth, Trends, COVID-19 Impact, and Forecasts (2022 - 2027)

The Preventive Vaccines Market is segmented by Vaccine Type (Live/Attenuated Vaccines, Inactivated Vaccines, Subunit Vaccines, Toxoid Vaccines and Others), By Disease Type (Pneumococcal, Poliovirus, Hepatitis, Influenza, Measles, Mumps, and Rubella (MMR), and Other Disease Types) and Geography (North America, Europe, Asia-Pacific, Middle East & Africa, and South America). The report offers the value (in USD million) for the above segments.

Market Snapshot

Preventive Vaccines Market Summary
Study Period: 2019-2027
Base Year: 2021
Fastest Growing Market: Asia-Pacific
Largest Market: North America
CAGR: 6.1 %
Preventive Vaccines Market Major Players

Need a report that reflects how COVID-19 has impacted this market and its growth?

Market Overview

The Preventive Vaccines Market is projected to register a CAGR of 6.1% during the forecast period (2022-2027).

Vaccine development has been rapidly increasing in recent years during the pandemic, and their use is also increasing in many parts of the world. Major firms' practices, such as continual research and development for bringing new technologies to save costs and shorten time, will drive the market worldwide. The demand for immunizations has risen in recent years as the incidence of viral and bacterial infectious illnesses has increased. Vaccinations are primarily given to people of all ages to boost their immune systems and provide protection against various infectious diseases throughout their lives. According to National Center for Immunization and Respiratory Diseases, data updated on June 19, 2022, the COVID-19 immunizations, includes protection against being hospitalized due to a COVID-19 and new infections. COVID-19 vaccinations available in the United States and across the world are effective in preventing serious illness, hospitalization, and even death, especially in those who have been boosted. The World Health Organization (WHO) states that  billions of people have been vaccinated against COVID-19. According to statistics updated on 13 April 2022 by WHO, getting vaccinated is one of the most critical things one can do to protect oneself against COVID-19, assist end the pandemic, and prevent new versions from arising.

Increased government support for vaccine development, increased R&D spending, the advent of speedier vaccine development methods, and advancements in vaccine design are all factors that will drive market expansion in the future years. However, the high cost of vaccine storage and shipping, as well as strict restrictions for vaccine licencing, may limit market growth. Governments all around the world are implementing awareness initiatives in response to the rising occurrence of diseases among youngsters. Furthermore, substantial developments in vaccine technology, such as the introduction, development, and use of the hepatitis B vaccine, are expected to boost corporate growth in the coming years. MNCs' research, innovation, and development in the field of vaccine production, which draws on their extensive experience, are advantages for this region. Increased illness prevalence in children and adults will drive demand for more preventative vaccines in the coming years. To meet this demand, major pharmaceutical companies such as Merck, Pfizer, GlaxoSmithKline, and Sanofi are likely to play a significant role. With the arrival of new improved preventative and therapeutic vaccinations, the World Health Organization (WHO) in 2020 predicts that the market has a significant potential. Due to the rising frequency of numerous infectious diseases and improved economic indicators, China and India are likely to see a surge in demand and achieve maximum growth over the next ten years.

Scope of the Report

As per the scope of this report, preventive vaccines are used to prevent infection with viruses, which causes serious disease. The vaccine is made of a weakened form of the virus that cannot cause disease but causes the body’s immune system to make antibodies that destroy the hepatitis virus. The Preventive Vaccines Market is segmented by Vaccine Type (Live/Attenuated Vaccines, Inactivated Vaccines, Subunit Vaccines, Toxoid Vaccines, and Others), By Disease Type (Pneumococcal, Poliovirus, Hepatitis, Influenza, Measles, Mumps, and Rubella (MMR), and Other Disease Types) and Geography (North America, Europe, Asia-Pacific, Middle East & Africa, and South America). The market report also covers the estimated market sizes and trends for 17 different countries across major regions, globally. The report offers the value (in USD million) for the above segments.

By Vaccine Type
Live/Attenuated Vaccines
Inactivated Vaccines
Subunit Vaccines
Toxoid Vaccines
Others
By Disease Type
Pneumococcal
Poliovirus
Hepatitis
Influenza
Measles, Mumps, and Rubella (MMR)
Other Disease Types
Geography
North America
United States
Canada
Mexico
Europe
Germany
United Kingdom
France
Italy
Spain
Rest of Europe
Asia-Pacific
China
Japan
India
Australia
South Korea
Rest of Asia-Pacific
Middle-East and Africa
GCC
South Africa
Rest of Middle-East and Africa
South America
Brazil
Argentina
Rest of South America

Report scope can be customized per your requirements. Click here.

Key Market Trends

Hepatitis Vaccines are Expected to Exhibit High Growth Rate over the Forecast Period

According to World Health Organization (WHO), data published on 2022 estimated that Hepatitis B or C affects roughly 354 million people globally, and for the vast majority, diagnosis and treatment are out of reach. As a result, the global prevalence of hepatitis is rising, raising worries about immunisation. The rising number of Hepatitis cases has prompted national governments and healthcare organisations to take initiatives to raise disease awareness and coordinate vaccination drives in high-risk areas. For instance, according to data provided by the World Health Organization (WHO) in 2022, WHO's global hepatitis plan, which has been supported by all WHO Member States, seeks to reduce new hepatitis infections by 90% and fatalities by 65% between 2016 and 2030. The market is expected to increase as long as market participants continue to promote Hepatitis A vaccinations. For example, VBI Vaccines Inc. announced in December 2021 that the United States Food and Drug Administration (FDA) has approved PreHevbrio for the prevention of infection caused by all known subtypes of the hepatitis B virus (HBV) in individuals aged 18 and up. Hepatitis vaccines are available for both hepatitis A and hepatitis B prevention, and they work by raising a person's immunity, preventing consequences including liver failure and cancer.

Hepatitis B is more common than hepatitis A worldwide. The hepatitis B virus causes a potentially fatal liver infection called hepatitis B. (HBV). It is a significant global health issue. It can lead to persistent infection and increases the chance of cirrhosis and liver cancer mortality. According to data published by the World Health Organization (WHO) on June 2, 2022, 296 million people had chronic hepatitis B infection in 2019, with 1.5 million new infections per year. Hepatitis B caused an estimated 820 000 deaths in 2019, largely due to cirrhosis and hepatocellular carcinoma, which is a type of primary liver cancer. The hepatitis vaccine market is expected to develop as the global incidence of hepatitis rises. Furthermore, growing public knowledge of the benefits of hepatitis immunisation will help the market grow even more.

Estimated Acute Cases of Hepatitis C Infection (%) in the United States, as per the data

North America is Expected to Hold a Significant Share in the Market and Expected to do Same in the Forecast Period

North America dominated the global market and accounted for the largest revenue share, owing to its rapidly increasing healthcare infrastructure and rising healthcare spending. The surge is powered by a huge pharmaceutical sector, world-class healthcare infrastructure, and high citizen spending on healthcare. COVID-19 vaccines and other disease vaccines are in the pipeline and undergoing clinical testing, as part of ongoing research to prevent pandemic spread. The market is likely to grow as the number of vaccines in development increases. In addition, the market is boosted by several immunization programs, government and non-government initiatives, and an increase in demand for combined vaccines. For example, according to data published by the National Center for Immunization and Respiratory Diseases on June 9, 2022, retail pharmacies in the United States have administered and reported more than 254.3 million doses across programs, including 8 million doses administered onsite to long-term care facilities in the early days of the vaccination program.

During the projection period, however, the costs of vaccine storage and delivery, as well as limited reimbursement coverage, are expected to hinder the market. Furthermore, pharmaceutical businesses in the region are focusing on COVID-19-related diagnostics, therapies, health technologies, and vaccinations, as well as evaluating the efficacy of existing treatments. For instance, in May 2022, GSK plc announced that it has entered into a definitive agreement to acquire Affinivax, Inc., a clinical-stage biopharmaceutical company based in Cambridge, Boston, Massachusetts, for a USD 2.1 billion upfront payment and up to USD 1.2 billion in potential development milestones. The deal is intended to strengthen GSK's vaccine R&D pipeline, provide it access to a new, potentially revolutionary technology, and expand its scientific footprint in the Boston area. All these variables are expected to have an impact on the market's growth.

Preventive Vaccines Market - Growth Rate by Region

Competitive Landscape

The Preventive Vaccines Market is fragmented competitive and consists of several major players. In terms of market share, few of the major players are currently dominating the market. Some of the companies which are currently dominating the market are AstraZeneca PLC, Emergent BioSolutions Inc., Daiichi Sankyo Co. Ltd, GlaxoSmithKline PLC, Johnson & Johnson, Merck & Co., Novavax Inc., Pfizer Inc., Sanofi SA, Takeda Pharmaceutical Co. Ltd.

Major Players

  1. AstraZeneca PLC

  2. Emergent BioSolutions Inc

  3. GlaxoSmithKline PLC

  4. Johnson & Johnson

  5. Merck & Co

Preventive Vaccines Market Concentration

Recent Development

In May 2022, Moderna, Inc. and Takeda announced to transfer the marketing authorization in Japan for Moderna’s COVID-19 vaccine SpikevaxTM (mRNA-1273) from Takeda to Moderna in Japan as of August 1, 2022.

In January 2022, Daiichi Sankyo Company, Limited announced that it has initiated a trial in Japan to investigate a booster dose of DS-5670, an mRNA vaccine against the novel coronavirus infectious disease (COVID-19).

Table of Contents

  1. 1. INTRODUCTION

    1. 1.1 Study Assumptions & Market Defination

    2. 1.2 Scope of the Study

  2. 2. RESEARCH METHODOLOGY

  3. 3. EXECUTIVE SUMMARY

  4. 4. MARKET DYNAMICS

    1. 4.1 Market Overview

    2. 4.2 Market Drivers

      1. 4.2.1 Growing Prevalence of Infectious Diseases

      2. 4.2.2 Innovative Technology in Vaccine Development

      3. 4.2.3 Increased Funding from Government and International Organizations

      4. 4.2.4 Increasing Government Focus on Immunization Programs

    3. 4.3 Market Restraints

      1. 4.3.1 Shortage Of Healthcare Personnel In Information Technology And Radiology Sector

      2. 4.3.2 Cybersecurity And Privacy Concerns

    4. 4.4 Porter's Five Force Analysis

      1. 4.4.1 Threat of New Entrants

      2. 4.4.2 Bargaining Power of Buyers/Consumers

      3. 4.4.3 Bargaining Power of Suppliers

      4. 4.4.4 Threat of Substitute Products

      5. 4.4.5 Intensity of Competitive Rivalry

  5. 5. MARKET SEGMENTATION

    1. 5.1 By Vaccine Type

      1. 5.1.1 Live/Attenuated Vaccines

      2. 5.1.2 Inactivated Vaccines

      3. 5.1.3 Subunit Vaccines

      4. 5.1.4 Toxoid Vaccines

      5. 5.1.5 Others

    2. 5.2 By Disease Type

      1. 5.2.1 Pneumococcal

      2. 5.2.2 Poliovirus

      3. 5.2.3 Hepatitis

      4. 5.2.4 Influenza

      5. 5.2.5 Measles, Mumps, and Rubella (MMR)

      6. 5.2.6 Other Disease Types

    3. 5.3 Geography

      1. 5.3.1 North America

        1. 5.3.1.1 United States

        2. 5.3.1.2 Canada

        3. 5.3.1.3 Mexico

      2. 5.3.2 Europe

        1. 5.3.2.1 Germany

        2. 5.3.2.2 United Kingdom

        3. 5.3.2.3 France

        4. 5.3.2.4 Italy

        5. 5.3.2.5 Spain

        6. 5.3.2.6 Rest of Europe

      3. 5.3.3 Asia-Pacific

        1. 5.3.3.1 China

        2. 5.3.3.2 Japan

        3. 5.3.3.3 India

        4. 5.3.3.4 Australia

        5. 5.3.3.5 South Korea

        6. 5.3.3.6 Rest of Asia-Pacific

      4. 5.3.4 Middle-East and Africa

        1. 5.3.4.1 GCC

        2. 5.3.4.2 South Africa

        3. 5.3.4.3 Rest of Middle-East and Africa

      5. 5.3.5 South America

        1. 5.3.5.1 Brazil

        2. 5.3.5.2 Argentina

        3. 5.3.5.3 Rest of South America

  6. 6. COMPETITIVE LANDSCAPE

    1. 6.1 Company Profiles

      1. 6.1.1 AstraZeneca PLC

      2. 6.1.2 Emergent BioSolutions Inc.

      3. 6.1.3 Daiichi Sankyo Co. Ltd

      4. 6.1.4 GlaxoSmithKline PLC

      5. 6.1.5 Johnson & Johnson

      6. 6.1.6 Merck & Co.

      7. 6.1.7 Novavax Inc.

      8. 6.1.8 Pfizer Inc.

      9. 6.1.9 Sanofi SA

      10. 6.1.10 Takeda Pharmaceutical Co. Ltd

    2. *List Not Exhaustive
  7. 7. MARKET OPPORTUNITIES AND FUTURE TRENDS

**Competitive Landscape covers- Business Overview, Financials, Products and Strategies and Recent Developments
You can also purchase parts of this report. Do you want to check out a section wise price list?

Frequently Asked Questions

The Global Preventive Vaccines Market market is studied from 2019 - 2027.

The Global Preventive Vaccines Market is growing at a CAGR of 6.1% over the next 5 years.

Asia-Pacific is growing at the highest CAGR over 2021- 2026.

North America holds highest share in 2021.

AstraZeneca PLC, Emergent BioSolutions Inc, GlaxoSmithKline PLC, Johnson & Johnson, Merck & Co are the major companies operating in Global Preventive Vaccines Market.

80% of our clients seek made-to-order reports. How do you want us to tailor yours?

Please enter a valid email id!

Please enter a valid message!